Combination ‘promising’ for advanced classical Hodgkin lymphoma

ByAshley Killen

ByTatyana Feldman, MD

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma, according to study results.

Efficacy results show the combination is “a promising treatment” for adults with bulky stage II or stage III/stage IV disease, Tatyana Feldman, MD, director of the T-cell lymphoma program at Hackensack Meridian John Theurer Cancer Center, and colleagues concluded.

The combination also appeared well-tolerated, findings from a single-arm phase 2 study presented at ASH Annual Meeting and Exposition showed.

Healio spoke with Feldman about the study results and their potential implications.

Published by:

Sources/Disclosures

Collapse

Source:

Lee H, et al. Abstract 314. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Disclosures: Feldman reports consulting/advisory roles with, speakers bureau roles with or other financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genmab, Genomic Testing Cooperative, Janssen, Karyopharm Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Secura Bio, Seagen and Takeda. Please see the abstract for all other researchers’ relevant financial disclosures.

ASH Annual Meeting and Exposition

Read more

Combination ‘promising’ for advanced classical Hodgkin lymphoma

Related Content